Arca
Skip to content
Tools
Tools

Mycosis fungoides

Drug research and approvals for mycosis fungoides: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 22, 2026, 29 studies of mycosis fungoides are recruiting on ClinicalTrials.gov, Health Canada has authorized 2 drug trials for it since 2013, FDA has 3 approved and 5 open orphan designations naming it, and the EU has 2 authorised medicines for it.

  • Recruiting worldwide: 29
  • Trials authorized in Canada: 2
  • FDA orphan approvals: 3
  • EU medicines: 2

Recruiting now

Newest posted first, of 29 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 6

Phase 3 6

Phase 2 12 of 17

Phase 1 or earlier 12 of 33

How its trials ended

231 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 82 whose ending is known, 30% met their primary endpoint, 0% missed it and 70% stopped early.

  • Completed, result not reported8738%
  • Ongoing5022%
  • Met its primary endpoint2511%
  • Stopped: other or unclear2511%
  • Stopped: enrollment or feasibility177%
  • Status unknown125%
  • Stopped: sponsor or business decision73%
  • Stopped: funding52%
  • Stopped: lack of efficacy31%

Trials authorized in Canada

Newest first; search them all in Canada trials
Nov 18, 2022An interventional, single-arm, open-label phase II study investigating the efficacy and safety of ANTI-PD1 immunotherapy for the treatment of patients with…Libtayo (cemiplimab)Alberta Health Services, Cross Cancer InstitutePending
Dec 13, 2018A phase 1 dose escalation trial of intratumoral injections of TTI-621 in subjects with relapsed and refractory percutaneously-accessible solid tumors and…TTI-621 (SIRPA-IGG1 fc)Trillium TherapeuticsPending

FDA orphan designations

Approved first, then open designations, newest first
Aug 8, 2018PoteligeoPOTELIGEO is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after…Kyowa Kirin Pharmaceutical Development Inc.Approved
Nov 9, 2017AdcetrisTreatment for adult patients with CD30-expressing mycosis fungoides who have received prior systemic therapySeagen Inc.Approved
Aug 23, 2013ValchlorTopical treatment of Stage 1A and 1B mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed…Helsinn Birex Pharmaceuticals Ltd.Approved
Sep 18, 2017PriliximabTreatment of mycosis fungoides (MF)Onco Therapies, Inc.Designated
Mar 30, 2017MRG-106 oligonucleotide inhibitor of microRNA miR-155-5pTreatment of mycosis fungoidesmiRagen Therapeutics, Inc.Designated
Nov 23, 2010NaloxoneTopical treatment of pruritus associated with mycosis fungoidesElorac, Inc.Designated
Aug 13, 2004Human anti-CD4 monoclonal antibodyTreatment of mycosis fungoidesEmergent Product Development Seattle, LLCDesignated
Oct 15, 1990Methotrexate with laurocapramTopical treatment of mycosis fungoides.Echo Therapeutics, Ltd.Designated

Medicines authorised in the EU

Newest first
Nov 22, 2018PoteligeoMogamulizumab · orphanKyowa Kirin Holdings B.V.EMA ↗
Mar 3, 2017LedagaChlormethine · orphanHelsinn Birex Pharmaceuticals Ltd.EMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.